Lurbinectedin in patients with pretreated germline BRCA1/2 metastatic breast cancer
16496
post-template-default,single,single-post,postid-16496,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Lurbinectedin in patients with pretreated germline BRCA1/2 metastatic breast cancer

Home > Blogs  > Lurbinectedin in patients with pretreated germline BRCA1/2 metastatic breast cancer

19 Sep Lurbinectedin in patients with pretreated germline BRCA1/2 metastatic breast cancer

Posted at 10:18h in Blogs by

In patients with pretreated germline BRCA1/2 breast cancer who had received a median of two prior chemotherapy lines for advanced disease, treatment with Lurbinectedin (a selective inhibitor of oncogenic transcription) showed an ORR of 28.6% (95% CI 11.3% to 52.2%), median DoR was 8.6 months, median PFS was 4.1 months and median OS was 16.1 months. No objective response was observed among patients who had received prior poly (ADP-ribose) polymerase inhibitors. This study showed the activity of lurbinectedin in germline BRCA1/2 breast cancer with a predictable and manageable safety profile. (Ref: Boni V et al, ESMO Open. Aug 26, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6977591785254465536

No Comments

Sorry, the comment form is closed at this time.